European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding

June 12, 2018 Group News

European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR 7.25 million in additional funding

Amsterdam, The Netherlands – 12 June 2018
read more

ESPERITE NV (ESP) LAUNCHS NEW AGAATA Dx, DIAGNOSTIC SYSTEM WITH MACHINE LEARNING CAPABILITIES FOR GENETIC CLINICAL LABORATORIES.

June 6, 2018 Group News

AGAATA delivers clinical reports in the fields of Reproductive Health, Oncology and Inherited Diseases.

Amsterdam, The Netherlands – 06 June 2018

read more

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

May 17, 2018 Group News

Esperite NV (ESP) with The Cell Factory has signed the agreement with the PHARM CRO to start preparation for the first-in-man clinical trials in treatment of Crohn’s disease.

Amsterdam, The Netherlands – 17 May 2018

read more

Esperite’s (ESP) The Cell Factory received European funding to develop the 2nd generation EVs drug for treatment of Stroke

May 3, 2018 Group News

Esperite’s biotech company The Cell Factory, Belgium has received funding from the European Union’s Horizon 2020 research and innovation Programme for development and characterization of the extracellular vesicles (EVs) drug CF-MEV-126 for treatment of stroke. The project is focused on the development of the 2nd generation EVs drug, with enhanced anti-inflammatory and neuroprotective activities.

Amsterdam, The Netherlands – 3 May 2018

read more

Esperite (ESP), The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV’s drugs for treatment of inflammatory diseases

March 29, 2018 Group News

Esperite with its biotech company The Cell Factory has acquired from OPBG the full rights to the IP and the international patent family covering the invention and the therapeutic use of the EV’s products. In collaboration with Women’s and Children’s Health Department of the University of Padua, Italy they are presenting the new generation EV’s biologic drugs bio-activated with Annexin V targeting multiple inflammatory diseases i.e.: Crohn’s disease, drug resistance epilepsy, stroke. The experimental results will be presented during GISM congress in Assisi, Italy in April and ISEV meeting in Barcelona, Spain in May 2018.

Amsterdam, the Netherlands – 29 March 2018

read more

Page 1 of 4112345...102030...Last »